Arcellx (NASDAQ:ACLX – Free Report) had its price objective boosted by Bank of America from $84.00 to $100.00 in a research ...

Analyst John Newman of Canaccord Genuity maintained a Buy rating on Seres Therapeutics (MCRB – Research Report), retaining the price ...

Truist raised the firm’s price target on Arcellx (ACLX) to $136 from $87 and keeps a Buy rating on the shares after its Q3 results. The ...

Arcellx (NASDAQ:ACLX – Free Report) had its target price increased by Robert W. Baird from $77.00 to $106.00 in a research ...

Is Arcellx, Inc. (ACLX) one of those stocks right now? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.

Roughly a year ago, Gilead Sciences revealed that it was laying off about 7% of Kite Pharma’s workforce in a bid to refresh ...

Across the recent three months, 11 analysts have shared their insights on Arcellx (NASDAQ:ACLX), expressing a variety of opinions spanning from bullish to bearish. The table below provides a ...

Investing.com - Arcellx (NASDAQ: ACLX) reported third quarter EPS of $-0.48, $0.14 worse than the analyst estimate of $-0.34. Revenue for the quarter came in at $26.03M versus the consensus ...